To establish ourselves as a world-class leader in the fight against HIV, AIDs and other autoimmune diseases, Ranbaxy has created several different lines of highly active antiretroviral therapy (HAART) treatments. These products are currently the largest selection of biogeneric antiretroviral drugs (ARVs) in the world. These ARVs are highly effective in controlling the HIV/AIDS virus and in managing opportunistic infections. All of our HAART regimens are produced at our WHO prequalified, and USFDA approved state-of-the-art biogeneric manufacturing facility in Himachal Pradesh, India.
More than ARVs are needed to successfully treat HIV. Patients that receive alternative therapy in addition to the use of anti-opportunistic infection drugs and ongoing observation are successfully able to manage their condition to improve their quality of life.
Ranbaxy is proud to offer a complete line of ARVs, anti-infective regimens for opportunistic infections and diagnostic solutions to effectively screen, test and monitor AIDS/HIV infections to improve overall health and life expectancy.
Our complete line of drugs include:
Our commitment and dedication to creating world-class drugs and treatment regimens is not limited to the fight against HIV. Ranbaxy is also a world-class producer and supplier of premium quality generic and branded active pharmaceutical ingredient and non-active pharmaceutical ingredient drugs and medicines.